Agios Pharmaceuticals, Inc. Share Price & Technical Analysis
AGIO · $27.23 (-0.77%)
Healthcare / Biotechnology
$27.23
-0.77%
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment …
Price chart
Seasonality
Jun has 4 positive and 1 negative years (last 5 years shown)
-6% return in Jun, 11% avg return in past 3 year Jun month.
7% return in 2026, 17% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 1% | 11% | 13% | -17% | 5% | -6% | – | – | – | – | – | – | 7% |
| 25 | 5% | 5% | -17% | 2% | 10% | 3% | 12% | 1% | 6% | 8% | -32% | -5% | -3% |
| 24 | 2% | 42% | -10% | 11% | 12% | 17% | 8% | 2% | -3% | 0% | 32% | -45% | 69% |
| 23 | 4% | -14% | -9% | 0% | 11% | 12% | -6% | 3% | -10% | -15% | 6% | 1% | -16% |
| 22 | -6% | 0% | -7% | -24% | -11% | 13% | -3% | 20% | 3% | -4% | 8% | -6% | -17% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.65B
P/E ratio
—
52W high
$46.00
52W low
$22.24
Volume
5,68,945
Beta
0.59
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹35,920
Abbott Laboratories Cede…
₹33,540
Eli Lilly And Company Ce…
₹30,700
Unitedhealth Group Inc C…
₹18,590
₹7,059
Frequently asked questions
- What is Agios Pharmaceuticals, Inc. share price today?
- Agios Pharmaceuticals, Inc. (AGIO) last traded around $27.23 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AGIO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AGIO. Download the app for real-time alerts.
- How can I analyze Agios Pharmaceuticals, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.